Dare Bioscience (DARE) Research & Development (2013 - 2026)
Dare Bioscience's (DARE) quarterly Research & Development came in at $622041.0 in Q4 2025, down 81.35% YoY from $3.3 million in Q4 2024, and down 47.07% on a QoQ basis from $1.2 million in Q3 2025.
Dare Bioscience (DARE) Research & Development (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Research & Development data on file, last reported at $622041.0 in Q4 2025.
- Quarterly Research & Development fell 81.35% year-over-year to $622041.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.5 million (down 61.39% YoY) and the FY2025 annual result came in at $5.5 million, down 61.39% from the prior year.
- Research & Development slipped to $622041.0 in Q4 2025, from $1.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $13.0 million in Q4 2022 to a low of $622041.0 in Q4 2025.
- A 5-year average of $5.1 million and a median of $5.0 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2021 — Research & Development surged 140.7% — and 2025, when it sank 81.35%.
- Tracing DARE's Research & Development over 5 years: stood at $7.1 million in 2021, then soared by 82.35% to $13.0 million in 2022, then plunged by 70.72% to $3.8 million in 2023, then slipped by 12.2% to $3.3 million in 2024, then slumped by 81.35% to $622041.0 in 2025.
- The last three Research & Development figures came in at $622041.0 (Q4 2025), $1.2 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Dare Bioscience | 11.91 Mn | -705,728.22 | -132,343.00 | 241,966.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 241,966.00 |
| Dec 31, 2025 | 622,041.00 |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Dec 31, 2024 | 3.34 Mn |
| Sep 30, 2024 | 2.68 Mn |
| Jun 30, 2024 | 4.93 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 3.80 Mn |
| Sep 30, 2023 | 6.67 Mn |
| Jun 30, 2023 | 6.04 Mn |
| Mar 31, 2023 | 5.02 Mn |
| Dec 31, 2022 | 12.98 Mn |
| Sep 30, 2022 | 4.46 Mn |
| Jun 30, 2022 | 6.80 Mn |
| Mar 31, 2022 | 5.81 Mn |
| Dec 31, 2021 | 7.12 Mn |
| Sep 30, 2021 | 10.43 Mn |
| Jun 30, 2021 | 7.34 Mn |